Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:IDT
NYSE:IDTTelecom

IDT (IDT) Q1: EPS Outperformance Reinforces Bullish Margin-Expansion Narrative

IDT (IDT) just opened fiscal 2026 with Q1 revenue of $322.8 million and basic EPS of $0.89, setting the tone for another data heavy year for investors tracking its earnings trajectory. The company has seen quarterly revenue move from $309.6 million in Q1 2025 to $322.8 million in Q1 2026, while basic EPS stepped up from $0.68 to $0.89 over the same stretch, framing a story in which profit per share is edging ahead of the top line. With net income and margins nudging higher in the background,...
NYSE:WLY
NYSE:WLYMedia

Is Wiley a Bargain After a 25% Slide and DCF Value Near 45 Dollars?

If you have been wondering whether John Wiley & Sons at around $32 is a bargain or a value trap, you are not alone and this article is going to tackle that question head on. Despite being a long established name in publishing and research, the stock has had a rough ride lately, falling about 10.9% over the last week, 15.2% over the last month and roughly 24.9% year to date, which naturally raises questions about whether the market has become too pessimistic. Some of this share price weakness...
NYSE:PB
NYSE:PBBanks

How Investors Are Reacting To Prosperity Bancshares (PB) Earnings Beat And Insider Stock Sales

Earlier this week, Prosperity Bancshares reported third-quarter 2025 earnings per share of US$1.45, an 8.2% year-over-year increase that exceeded expectations, while director Ned S. Holmes sold US$77,096 of company stock in several transactions. Beyond the insider sales, the earnings call highlighted management’s focus on growth initiatives and a constructive outlook, which has drawn renewed attention from analysts and investors. Now we’ll examine how Prosperity Bancshares’...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

Is Avadel Pharmaceuticals Still Attractive After a 113.4% One Year Surge in 2025?

If you are wondering whether Avadel Pharmaceuticals at around $21 a share still has room to run or is already priced for perfection, you are not alone. This breakdown is designed to give you a clear, valuation focused view. The stock has dipped about 0.7% over the last week, but it is still up 12.6% over the past month and 94.0% year to date, with a 113.4% gain over the last year shifting how the market thinks about its risk and reward profile. Much of that surge has been driven by growing...